BR112020004419A2 - formas sólidas de 2-(5-(4-(2-morfolinoetóxi)fenil)piridin-2-il)-n-benzilacetamida - Google Patents

formas sólidas de 2-(5-(4-(2-morfolinoetóxi)fenil)piridin-2-il)-n-benzilacetamida Download PDF

Info

Publication number
BR112020004419A2
BR112020004419A2 BR112020004419-9A BR112020004419A BR112020004419A2 BR 112020004419 A2 BR112020004419 A2 BR 112020004419A2 BR 112020004419 A BR112020004419 A BR 112020004419A BR 112020004419 A2 BR112020004419 A2 BR 112020004419A2
Authority
BR
Brazil
Prior art keywords
approximately
polymorph
compound
fact
weeks
Prior art date
Application number
BR112020004419-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael P. Smolinski
Original Assignee
Athenex HK Innovative Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020004419(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Athenex HK Innovative Limited filed Critical Athenex HK Innovative Limited
Publication of BR112020004419A2 publication Critical patent/BR112020004419A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112020004419-9A 2017-09-07 2018-09-07 formas sólidas de 2-(5-(4-(2-morfolinoetóxi)fenil)piridin-2-il)-n-benzilacetamida BR112020004419A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
US62/555,390 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE

Publications (1)

Publication Number Publication Date
BR112020004419A2 true BR112020004419A2 (pt) 2020-09-08

Family

ID=65517772

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020004419-9A BR112020004419A2 (pt) 2017-09-07 2018-09-07 formas sólidas de 2-(5-(4-(2-morfolinoetóxi)fenil)piridin-2-il)-n-benzilacetamida

Country Status (22)

Country Link
US (4) US10669236B2 (https=)
EP (2) EP4674486A3 (https=)
JP (3) JP7843116B2 (https=)
KR (2) KR102691700B1 (https=)
CN (2) CN118439992A (https=)
AU (2) AU2018330163B2 (https=)
BR (1) BR112020004419A2 (https=)
CA (1) CA3074831A1 (https=)
DK (1) DK3679016T3 (https=)
ES (1) ES3056703T3 (https=)
FI (1) FI3679016T3 (https=)
HR (1) HRP20260002T1 (https=)
IL (2) IL326637A (https=)
LT (1) LT3679016T (https=)
MX (2) MX2020002622A (https=)
PL (1) PL3679016T3 (https=)
PT (1) PT3679016T (https=)
RS (1) RS67706B1 (https=)
SG (1) SG11202001868RA (https=)
SM (1) SMT202500467T1 (https=)
TW (1) TWI815820B (https=)
WO (1) WO2019051147A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
WO2026022219A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Injectable formulations comprising tirbanibulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DK1390377T3 (da) * 2001-05-22 2006-06-19 Pfizer Prod Inc Ny krystalform af azithromycin
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
BRPI0605937A2 (pt) * 2005-09-13 2009-05-26 Sicor Inc processo para a sìntese de brometo de rocurÈnio
WO2008002676A2 (en) * 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008039421A2 (en) * 2006-09-28 2008-04-03 Merck & Co., Inc. Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
JP2010527996A (ja) * 2007-05-22 2010-08-19 ウルティモルフィクス・テクノロジーズ・ベー・フェー テノホビルジソプロキシル−ヘミフマル酸共結晶
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
WO2018165647A1 (en) 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis

Also Published As

Publication number Publication date
RU2020112539A (ru) 2021-10-08
TW201920160A (zh) 2019-06-01
TWI815820B (zh) 2023-09-21
KR20240119192A (ko) 2024-08-06
EP3679016B1 (en) 2025-11-05
RU2020112539A3 (https=) 2022-04-19
US11230527B2 (en) 2022-01-25
HRP20260002T1 (hr) 2026-02-27
SG11202001868RA (en) 2020-03-30
KR102691700B1 (ko) 2024-08-02
US20250115555A1 (en) 2025-04-10
US20190071402A1 (en) 2019-03-07
AU2023201010A1 (en) 2023-03-23
JP7843116B2 (ja) 2026-04-09
PT3679016T (pt) 2025-12-05
EP4674486A3 (en) 2026-03-25
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
CN111278808B (zh) 2024-04-26
AU2018330163B2 (en) 2023-02-02
DK3679016T3 (da) 2025-12-15
CN118439992A (zh) 2024-08-06
EP4674486A2 (en) 2026-01-07
AU2023201010B2 (en) 2024-10-03
WO2019051147A1 (en) 2019-03-14
AU2018330163A1 (en) 2020-03-26
US20200255380A1 (en) 2020-08-13
PL3679016T3 (pl) 2026-03-02
ES3056703T3 (en) 2026-02-24
CN111278808A (zh) 2020-06-12
FI3679016T3 (fi) 2025-12-12
LT3679016T (lt) 2026-02-10
US20220098152A1 (en) 2022-03-31
JP2020533412A (ja) 2020-11-19
MX2023001805A (es) 2023-03-13
JP2025131661A (ja) 2025-09-09
EP3679016A4 (en) 2021-09-29
IL326637A (en) 2026-04-01
US10669236B2 (en) 2020-06-02
IL272992A (en) 2020-04-30
JP2023157909A (ja) 2023-10-26
SMT202500467T1 (it) 2026-03-09
CA3074831A1 (en) 2019-03-14
MX2020002622A (es) 2020-10-01
RS67706B1 (sr) 2026-02-27
EP3679016A1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
US12215083B2 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
BR112020022738A2 (pt) formas cristalinas de um inibidor tlr7/tlr8
TWI870440B (zh) 活化素受體樣激酶抑制劑之鹽及晶體形式
CA2932560C (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof
KR20200139127A (ko) 설파살라진 염 조성물 및 이의 사용 방법
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
CN105566302B (zh) 二氢吲哚酮化合物及其盐的结晶
HK40115548A (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
KR20210141936A (ko) 셀리넥서의 공결정 형태
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
CN108658897A (zh) 乙酰苄胺哌嗪（啶）类衍生物及其作为脑神经保护剂的应用
HK40069001B (zh) 活化素受体样激酶抑制剂的盐和晶体形式
BR112018002614B1 (pt) Um processo para a preparação do composto n-(3,5-dimetilfenil)-n'-(2-trifluormetilfenil) guanidina
BRPI0712556A2 (pt) sais e modificaÇÕes cristalalinas das mesmas
PT1773811E (pt) Um hidrato cristalino variável de sal de hemissuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2- hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinicarbox amida

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: ATNX SPV, LLC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]